We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-3 of 3

Anti-bribery and corruption regulation increasing risks for life sciences companies
  • Baker McKenzie
  • Australia
  • October 11 2011

Some recent changes to anti-bribery and corruption laws in a number of jurisdictions, together with current high levels of regulator activity, have increased the compliance risks for both companies and individuals

Jane Woodhouse
  • Baker McKenzie